4 completed, 2 terminated, 2 unknown. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 4, Terminated 2, Unknown 2 |
Follow Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Myeloid Leukemia trials Research Report on Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP Dasatinib - Dasatinib, BCR-ABL | Phase 4 | Unknown | Shenzhen Second People's Hospital | 65 | 2019-12-01 | 2022-07-27 |
| Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Nilotinib - Chronic Myeloid Leukemia | Phase 4 | Completed | Novartis Pharmaceuticals | 171 | 2016-02-18 | 2022-07-22 |
| Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Imatinib - Chronic Myeloid Leukemia | Phase 4 | Unknown | Cttq | 90 | 2015-02-01 | 2014-12-15 |
| A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients 600mg/day of Imatinib, 400mg/day of Imatinib - Chronic Myeloid Leukemia | Phase 4 | Terminated | Dong-A ST Co., Ltd. | 55 | 2014-10-13 | 2018-06-15 |
| Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients Imatinib mesylate - Chronic Myeloid Leukemia | Phase 4 | Completed | University of Milano Bicocca | 112 | 2011-11-09 | 2019-12-03 |
| Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Nilotinib - Chronic Myeloid Leukemia | Phase 4 | Completed | Novartis Pharmaceuticals | 89 | 2008-08-01 | 2017-02-23 |
| Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib bone marrow aspiration - Chronic Myeloid Leukemia, Gastrointestinal Stromal Cell Tumors | Phase 4 | Terminated | University Health Network, Toronto | 68 | 2005-02-01 | 2009-02-13 |
| Glivec in Pediatric Chronic Myeloid Leukemia (CML) Imatinib mesylate 100 mg (Glivec) - Chronic Myeloid Leukemia | Phase 4 | Completed | Poitiers University Hospital | 44 | 2004-07-01 | 2016-10-11 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8) · Chromosome Aberrations (1) · Leukemia (1)
Bone Marrow Diseases (8) · Chronic Disease (8) · Disease Attributes (8) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Leukemia, Myeloid (8) · Myeloproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Leukemia (7)
Imatinib Mesylate (4) · nilotinib (2) · Dasatinib (1)
Novartis Pharmaceuticals (2) · Cttq (1) · Dong-A ST Co., Ltd. (1) · Poitiers University Hospital (1) · Shenzhen Second People's Hospital (1) · University Health Network, Toronto (1) · University of Milano Bicocca (1)
Canada (2) · Germany (2) · Brazil (1) · China (1) · France (1) · Israel (1) · Italy (1) · South Korea (1) · Spain (1)
Alessandra Iurlo, MD (1) · Arnon Nagler, MD (1) · Bruno Martino, MD (1) · Carlo Gambacorti-Passerini, MD (1) · Chul-won Choi, M.D. (1) · Chul-won Jung, M.D. (1) · Duk-yeon Cho, M.D. (1) · Elisabetta Abruzzese, MD (1) · Eros Di Bona, MD (1) · Ester Pungolino, MD (1) · Francesco Di Raimondo, MD (1) · Jeff Lipton, MD (1) · Jin-hee Park, M.D. (1) · Joo-sup Joeng, M.D. (1)
2015 (1)